| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
mTOR (mammalian target of rapamycin) and PI3Kα. mTOR inhibitor WYE-28 is a selective inhibitor of mTOR (IC50 = 0.08 nM) and also inhibits PI3Kα (IC50 = 6 nM).
|
|---|---|
| ln Vitro |
mTOR inhibitor WYE-28 is a potent mTOR inhibitor with an IC50 of 0.08 nM. It also inhibits PI3Kα with an IC50 of 6 nM. By inhibiting mTOR and PI3Kα, the compound blocks the PI3K/AKT/mTOR signaling pathway, leading to reduced cell growth and proliferation. mTOR inhibitor WYE-28 inhibits cell growth in LNCaP cells with an IC50 of less than 1 nM. The compound has a half-life of 13 minutes in nude mouse microsomes.
|
| ln Vivo |
No detailed in vivo activity data are publicly available for mTOR inhibitor WYE-28. As a potent mTOR and PI3Kα inhibitor, its in vivo effects would be expected to be related to the inhibition of the PI3K/AKT/mTOR signaling pathway, which could lead to reduced tumor growth.
|
| Enzyme Assay |
In vitro kinase assays for mTOR inhibitor WYE-28 are performed to evaluate its inhibitory activity against mTOR and PI3Kα. The kinases are incubated with peptide substrates and ATP in the presence of varying concentrations of the compound. The inhibition of kinase activity is measured by assessing the phosphorylation of the substrate, and IC50 values are calculated from the concentration-response curves.
|
| Cell Assay |
In vitro cell-based assays are conducted to evaluate the effects of mTOR inhibitor WYE-28 on mTOR and PI3K signaling and cell viability. Cells are treated with the compound, and the phosphorylation of mTOR targets (S6K1, 4E-BP1) and AKT is measured by Western blotting. Cell viability and proliferation are assessed using standard assays such as MTT or CCK-8. The compound's ability to inhibit cell growth in LNCaP cells has been demonstrated with an IC50 of less than 1 nM.
|
| Animal Protocol |
No detailed in vivo animal study protocols are publicly available for mTOR inhibitor WYE-28. In vivo studies would be conducted in animal models, such as tumor xenograft models, to evaluate the antitumor efficacy of the compound.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are publicly available for mTOR inhibitor WYE-28. The compound has a half-life of 13 minutes in nude mouse microsomes, indicating rapid metabolism.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for mTOR inhibitor WYE-28. As a potent mTOR and PI3Kα inhibitor, its toxicity profile would be expected to be related to its mechanism of action.
|
| References | |
| Additional Infomation |
WYE-28, an mTOR inhibitor, is a pyrazolopyrimidine compound with the structure 1H-pyrazolo[3,4-d]pyrimidine, substituted at positions 1, 4, and 6 with 1-(methoxycarbonyl)piperidin-4-yl, morpholin-4-yl, and 4-({[4-(hydroxymethyl)phenyl]carbamoyl}amino)phenyl, respectively. It is a potent inhibitor of mTOR (IC50 = 0.08 nM) and PI3Kα (IC50 = 6 nM). It can be used as an antitumor drug, an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, and an mTOR inhibitor. It belongs to the phenylurea, benzyl alcohol, carbamate, aromatic primary alcohol, pyrazolopyrimidine, morpholino, and piperidine carboxyl ester classes.
mTOR inhibitor WYE-28 (compound 28) is a selective mTOR inhibitor (IC50 = 0.08 nM) and PI3Kα inhibitor (IC50 = 6 nM). It inhibits cell growth in LNCaP cells with an IC50 of less than 1 nM and has a half-life of 13 minutes in nude mouse microsomes. The compound is a valuable research tool for studying the PI3K/AKT/mTOR signaling pathway. It is not approved for human therapeutic use and is strictly for research purposes. |
| Molecular Formula |
C30H34N8O5
|
|---|---|
| Molecular Weight |
586.641565799713
|
| Exact Mass |
586.265
|
| CAS # |
1062172-60-4
|
| PubChem CID |
24936050
|
| Appearance |
White to off-white solid powder
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
43
|
| Complexity |
916
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C(OC)=O)CCC(N2C3C(C=N2)=C(N2CCOCC2)N=C(C2=CC=C(NC(NC4=CC=C(CO)C=C4)=O)C=C2)N=3)CC1
|
| InChi Key |
DLIGFKRUAOAIBA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H34N8O5/c1-42-30(41)37-12-10-24(11-13-37)38-28-25(18-31-38)27(36-14-16-43-17-15-36)34-26(35-28)21-4-8-23(9-5-21)33-29(40)32-22-6-2-20(19-39)3-7-22/h2-9,18,24,39H,10-17,19H2,1H3,(H2,32,33,40)
|
| Chemical Name |
methyl 4-[6-[4-[[4-(hydroxymethyl)phenyl]carbamoylamino]phenyl]-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7046 mL | 8.5231 mL | 17.0462 mL | |
| 5 mM | 0.3409 mL | 1.7046 mL | 3.4092 mL | |
| 10 mM | 0.1705 mL | 0.8523 mL | 1.7046 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
